Pharma BD Deal Intelligence
Roche and Blueprint Medicines announced a substantial collaboration to advance pralsetinib, a therapeutic candidate targeting RET-driven cancers, with…
Blueprint Medicines to regain global rights to GAVRETO (pralsetinib) ex-Greater China following Roche's decision to terminate the collaboration for strategic…
Rigel Pharmaceuticals to acquire US rights to GAVRETO (pralsetinib) from Blueprint Medicines for up to $117.5M ($15M upfront, up to $102.5M milestones) plus…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
In July 2020 Roche entered an exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of pralsetinib (Gavreto), a selective RET kinase inhibitor, outside the United States (excluding Greater China, which was retained by CStone). Roche paid $675M upfront in cash plus a $100M equity investment in Blueprint ($775M total upfront), with Blueprint eligible for up to ~$1.05B in milestones plus tiered royalties on ex-US net sales; the companies were to co-commercialize in the US. On February 22, 2023 Roche notified Blueprint it would terminate the collaboration for strategic reasons (effective 12 months later, ~February 2024), and Blueprint regained global rights ex-Greater China. In February 2024 Blueprint sold US rights to pralsetinib to Rigel Pharmaceuticals for up to $117.5M (including up to $102.5M in milestones) plus tiered royalties. The Roche partnership is therefore terminated; Blueprint received roughly $1B in combined upfront and milestone payments over the life of the agreement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Blueprint Medicines Corporation (this deal) | 2020 | $1.7B | 35 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2020 deals · Roche Holding AG deals · Oncology deals